Perrigo sells Tysabri rights to Royalty Pharma in €2.7bn deal
Dublin-domiciled group finally gets hold of MS drug revenue it initially pursed from Elan in 2013
Perrigo makes board changes under pressure from activist investor
Dublin-based drugmaker was urged last year to explore a sale of its prescription business
Perrigo to review options for multiple sclerosis drug Tysabri
CEO John Hendrickson says drug faces increased competition and potential for wider use has failed to materialise
Perrigo shares slide as drugmaker slashes full-year forecast again
Company sales have halved since the company rejected Mylan takeover offer late last year
Valeant names Papa as its new CEO
Joseph Papa confirms position day after he resigns from the top spot at drugmaker Perrigo
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
The GlossOpens in new window
Read the digital edition of The Gloss magazine now
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices